(BFW) GVC Teams With Cerberus to Bid for Bwin, S. Times Reports


GVC Teams With Cerberus to Bid for Bwin, S. Times Reports
2015-07-26 08:12:04.903 GMT


By Abigail Moses
(Bloomberg) -- GVC Holdings Plc, Cerberus will offer GBP1b
for Bwin.party Digital Entertainment Plc, S. Times reports,
citing unidentified people familiar with the matter.

* GVC, Cerberus working on revised bid of GBp115-120/share;
GVC previously offered GBp110/share
* Bwin has already agreed GBp104p bid from 888 Holdings Plc
* Cerberus to provide debt financing for GVC’s new counter-
bid; cash-and-shares offer expected this week
* Cerberus declined to comment to Times; GVC said it was
“considering options”
* NOTE: July 21: GVC Considers Whether to Stay in Race to
Acquire Bwin.party


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Abigail Moses in London at +44-20-3525-2118 or
amoses5@bloomberg.net
To contact the editors responsible for this story:
Shelley Smith at +44-20-3525-2020 or
ssmith118@bloomberg.net
Abigail Moses

NY Post : Is Apple relying too heavily on the iPhone?

Almost everyone would agree it is far easier to argue on behalf of Apple than it is to examine the company and question its future.
But stocks are bought not for what a company has accomplished, but what a company plans to do tomorrow.
Fundamental business decisions like new products matter. And stock performance is all about sales and earnings and, most important, future sales and earnings — forecasts of corporate performance.
Perhaps that’s why investors have Apple trading at a below-market-price multiple of just 15 times earnings. By comparison, other major technology leaders like Facebook and Netflix trade at 93 and 251 times earnings, respectively.
Apple’s isn’t an A+ valuation for a firm growing at more than 30 percent.
Perhaps the market is predicting that while Apple has numerous products — iTunes, Music, iPads, Macs and Watches — it is essentially a one-trick company, with 63 percent of sales coming from the iPhone 6 alone.
It was an underwhelming sales number in iPhones that knocked the stock down more than 4 percent on Wednesday. As great a smartphone as the iPhone is, it does leave Apple vulnerable if the company doesn’t adapt.
The stock has been a great buy and hold for many years. But what would be the fundamental business signs or “tells” you should look for to see if Apple is going to keep growing?
Even the biggest companies slip up sometimes. One major screwup can happen, but two in a close time frame could indicate some real weakening in the armor.
The Apple Watch has been less than stellar in generating buzz, and since CEO Tim Cook did not want to talk sales numbers last week, that’s all we can go on.
And a strong case could be made that Apple missed the on-demand streaming market that Netflix seems to own.
Perhaps the billions Apple spent on developing a watch — when its best-selling product, the iPhone, eliminates the need for a watch — would have been better spent on building out Apple TV and/or buying Netflix.

>>> Barron's Summary: Positive on AMZN, UTX, AL, CUB, PNRA, MSFT, RY, CSCO

Barron's Summary: Positive on AMZN, UTX, AL, CUB, PNRA, MSFT, RY, CSCO 

Cover story: After 50 years at the helm of Berkshire Hathaway, Warren Buffett is still going strong, having made huge profits off the recent Heinz/Kraft deals, for which Wall Street hasnt given the firm enough credit; The company is better than ever despite the lackluster performance of its big equity portfolio, which is dominated by four stocks: AXP, KO, IBM, and WFC; Downside appears limited, given the companys rising book value and its willingness to aggressively repurchase stock at 1.2 times book value, backed by a formidable balance sheet with $58B in cash. 

Tech Trader: Positive on AMZN: Tiernan Ray says the important takeaway from online retailers earnings report was the strength of Amazon Web Services, which has profound implications for traditional computer companies, such as IT vendors IBM, HPQ, Dell, and CSCO; Cloud companies such as N, CTCT, NOW, and WDAY could become acquisition targets; Security providers such as PANW and FTNT, though expensive, could become more attractive for investors. 

Trader: Positive on UTX: The market is giving the company too little credit for its long-term outlook; Positive on RF: Large regional bank sells at a discount that seems too wide now that its credit profile has improved markedly and its operations have gained strength, and shares offer a nice margin of safety; Positive on AL: Though slowing economic growth and low jet-fuel prices could prompt airlines to delay the purchase of new planes, company trades at an inexpensive valuation and has sustainable tail winds. 

Features: 1) Positive on CUB: Companys card readers, passenger gates, and ticket-vending machines are essential products, and it has few competitors; a surge in demand could lead to 25% upside for shares; 2) Positive on PNRA: Food chain has long been plagued by long wait times in its restaurants, but a business upgrade that will bring self-serve kiosks should improve that and give shares a boost; 3) Positive on MSFT: Despite a weak quarterly report and the Nokia writedown, companys Windows giveaway strategy could make the franchise more valuable, and its transformation to a cloud-based software firm could lift shares 50% in three years; 4) Positive on RY: Banks RBC Capital unit had a 6.2% total return in the first half, taking first place in the semiannual Barrons-Zacks ranking of brokers focus-list stock recommendations.

Profile: Nathaniel August, founder of Mangrove Partners, which has returned more than 28% a year with relatively subdued volatility since its launch in April 2010. Interview: Rupal Bhansali, money manager, Ariel Investments (picks: MSFT, GSK, GILD, BIDU, BAP, ITUB).

Follow-Up: Positive on CSCO: Companys valuation could rise as investors begin to see it as an Internet-of-Things play rather than a moldy old hardware maker; Positive on GM: Barrons stands by its prediction shares will hit $50, knowing it will require whiplash-inducing gains through the end of the year. 

European Trader: Positive on BTG Plc: British healthcare company is still shaking off the effects of slower-than-expected sales for Varithena, but it is likely to make a full recovery. 

Asian Trader: Bridgewater Associates has changed its view on China, and now believes that the countrys stock market gyrations are negative for growth, and a further crash could tank Chinas growth in GDP for years.

Emerging Markets: For its reform agendawhich seeks to create millions of manufacturing jobsto work, India must abandon protectionist policies and expand global trade liaisons. 

Commodities: Zinc looks poised to shelter investors from the storm raging across metals markets, and it isnt likely to be part of a commodity price decline. 

CEO Spotlight: AA chief executive Klaus Kleinfeld has lessened the companys dependence on commodity products and changed the way alumina is priced, and it is increasingly becoming known as a manufacturing innovator. 

Streetwise: DDs spinoff of its specialty chemical business, now trading as CC, is the poster child for botched spinoffs this year.

WSJ : Teva in Advanced Talks to Buy Allergan’s Generic-Drug Unit

Teva in Advanced Talks to Buy Allergan’s Generic-Drug Unit


Is­raeli drug maker Teva Phar­ma­ceu­ti­cal In­dus­tries Ltd. MMTEVAMM is in talks to com­bine with Al­ler­gan MMAGNMM PLC’s big generic-drug busi­ness, ac­cord­ing to peo­ple fa­mil­iar with the mat­ter, in a move that would rep­re­sent a con­tin­u­a­tion of a boom in health­care deal­mak­ing and likely mean the end of Teva’s pur­suit of an­other ac­qui­si­tion.
A deal for the Al­ler­gan busi­ness, val­ued at about $45 bil­lion, could be an­nounced as early as Mon­day, one of the peo­ple said. The Al­ler­gan unit would be spun off and com­bined with Teva, which has a mar­ket value of $60 bil­lion, this per­son said.
Teva has been seek­ing to buy My­lan NV, a deal My­lan has been re­sist­ing as it pur­sues fel­low drug maker Per­rigo Co.

(BN) Fed Accidentally Released Confidential Staff Projections (3)


Fed Accidentally Released Confidential Staff Projections (3)
2015-07-24 23:55:37.462 GMT


(Updates with Fed press release on corrected projections
in 12th paragraph.)

By Christopher Condon and Craig Torres
(Bloomberg) -- The Federal Reserve said it inadvertently
released staff projections for interest rates and the economy
late last month, renewing doubts about its measures to protect
confidential information.
The Fed said in a statement Friday in Washington that
projections prepared for the June 16-17 Federal Open Market
Committee meeting were posted in error on a public website on
June 29. Staff projections are normally released with a five-
year lag when transcripts of FOMC meetings are published.
The disclosure follows congressional criticism over the
Fed’s handling of a leak of internal policy deliberations in
2012, which is being investigated by the House Financial
Services Committee.
“It regrettably appears once again that proper internal
controls are not in place to safeguard confidential Federal
Reserve information,” Jeb Hensarling, the Texas Republican who
chairs the House panel, said in an e-mailed statement.
In a separate incident in April 2013, a member of the Fed’s
congressional liaison staff accidentally e-mailed a copy of the
minutes of an FOMC meeting to more than 100 people, including
bank lobbyists and congressional staff, about 19 hours before
the minutes were due to be published.
The latest mishap “does raise questions as to what
procedures are in place to safeguard confidential information
and to make sure there is fair disclosure of market-sensitive
data,” said Mark Vitner, senior economist with Wells Fargo
Securities in Charlotte, North Carolina.

Yields Fall

Short-term Treasury yields briefly fell after the Fed’s
disclosure Friday. The yield on the two-year note slid two basis
points, or 0.02 percentage point, to 0.66 percent before
rebounding. The yield was at 0.68 percent at 2:54 p.m. in New
York.
The Fed said Friday that on June 29, “an updated package
of code was posted that inadvertently included three files
containing staff economic forecasts that are confidential FOMC
information.”
The Fed said it has since “implemented procedures to
prevent inadvertent posting” of internal material, said Susan
Stawick, a spokeswoman for the central bank who didn’t provide
details. “We’re committed to taking further steps if needed,”
she said.
The mistake was spotted by a Fed economist on Tuesday,
according to a Fed official who spoke on condition of anonymity.
It was then brought to the attention of the FOMC’s
administrative staff on Wednesday evening, according to Stawick.
The matter has been referred to the Fed’s Office of Inspector
General.

Rate Outlook

The inadvertent release comes at a sensitive time for
markets as investors seek to anticipate the timing of the first
increase in the Fed’s benchmark interest rate since 2006. The
Fed has said it will probably raise the rate this year, without
specifying when.
Late Friday, the Fed issued a statement saying that some of
the projections released inadvertently were, in fact, not the
staff forecasts provided to policy makers in June. It released a
table with the corrected projections.
The staff projections show the federal funds rate at 0.35
percent in the fourth quarter of 2015, up from the current range
of zero to 0.25 percent. The Fed said the staff forecasts don’t
represent the views of policy makers.
All the same, the release sent analysts scrambling to
evaluate the significance of the forecast, with some saying that
it implied just one quarter-point rate increase before the end
of the year.
Fed officials’ forecasts released in June implied two rate
increases in 2015, with the benchmark lending rate finishing the
year at 0.625 percent, according to their median estimate.

Eight Meetings

Before each of the eight scheduled yearly meetings of the
FOMC, staff economists with expertise in everything from
durable-goods spending to inflation construct estimates for
gross domestic product, inflation and unemployment.
To avoid recommending an interest-rate path to policy
makers, staff use a mechanical approach to derive a fed funds
rate for a given period based on the broader outlook, according
to the Fed official.
The 0.35 basis-point projection for the fourth quarter of
2015, for example, is the prevailing interest rate for the
period, and it isn’t a recommendation for one or two rate
increases, the official said.
“Does it change anything for the outlook for the Fed? No,
absolutely not,” said Aneta Markowska, chief U.S. economist at
Societe Generale SA in New York. “The FOMC already had these
when they met in June and they published theirs already, so they
took this into account and said we disagree.”

For Related News and Information:
Banks on Fed Staffer E-Mail List Get Accidental Leak of Minutes
Yellen Resists Demands to Give Congress Fed Leak Documents Now
Fed Leak Handed Traders Profitable Tip, Prompted Secret Inquiry
Top Stories:TOP<GO>
Top Fed stories: FEDU <GO>
Global Economic Watch: GEW <GO>
Central Bank Rates: CBRT <GO>

--With assistance from Jeff Kearns in Washington and Alexandra
Scaggs in New York.

To contact the reporters on this story:
Christopher Condon in Washington at +1-202-654-4333 or
ccondon4@bloomberg.net;
Craig Torres in Washington at +1-202-654-1220 or
ctorres3@bloomberg.net
To contact the editors responsible for this story:
Christopher Wellisz at +1-202-624-1862 or
cwellisz@bloomberg.net
Alister Bull

(FAS) Daimler sends self-propelled trucks on the highway

Daimler sends self-propelled trucks on the highway
The self-propelled car comes faster than expected. But that's not all. After informing the Sonntagszeitung Daimler will soon test whether or not self-propelled trucks on German motorways.

Later this year sends Daimler Trucks on highways, where the computer replaces the driver: "We are confident that we will in the coming weeks, the authorization for tests on German motorways get" Daimler Board of Management said Wolfgang Bernhard the Sunday newspaper: "And then we place off immediately ". There are nationwide tests planned, starting with Baden-Württemberg.

With the serial production of the semi-autonomous trucks Bernhard counted "in two or three years" before the appropriate car to hit the market: "Technically, we can get it back."

With the new technique, the road safety walkways, emphasized Bernhard: "97 percent of accidents based on human factors. The machine moves a total safer than man. "Quite unnecessary, the driver is not sure, with this technique. "There will always be a man sitting there who ensures that nothing happens," Bernhard said. "I can driving while completely handed over to the machine, also the braking and acceleration, the ride must monitor but."

FAS Read more in the Sunday newspaper from 26.07.2015. On the eve already in the FAS app and as e-paper .
Until fully autonomous driving even will be some time believes Wolfgang Bernhard, "because also want Apple, Google and the likes to be there." Terror let itself Daimler not by the new competition. ". We go on this issue front and let's not butter take the bread" When a company like Apple to even Daimler employees poaches him be troubled that the Board said: "This is an accolade for us if Apple decides: Your Business, the cars, which is so important, because we want to be there ".

FT : Economist shareholders in talks to buy out Pearson

Economist shareholders in talks to buy out Pearson

Pearson is in negotiations to sell its 50 per cent stake in the Economist Group, publisher of the Economist magazine, to other shareholders in the group including the investment vehicle of Italy’s Agnelli family.
The talks, which come in the same week as Pearson’s £844m sale of the FT Group to the Nikkei Group of Japan, could in effect complete the British company’s transformation from a diversified family conglomerate to a business focused solely on education. Its only large non-education interest would be a 47 per cent stake in Penguin Random House, the book publisher.

Exor, which is run by John Elkann, scion of the Agnelli family, said its role in the talks that may lead to the “possibility of increasing its investment in the group”.
It added: “Were it to proceed, Exor’s increased investment would in any event represent a minority shareholding in the the Economist . . . also reflecting Exor’s strong commitment to the editorial independence that lies at the heart of the Economist’s ethos and success.” Mr Elkann is on the Economist Group’s board and the group already owns 5 per cent.
A person close to Exor said, it would not be seeking the full stake being sold by Pearson.
Pearson’s stake would be worth about £400m, two people close to the situation said. That would give the Economist Group a similar valuation to the FT Group, even though its operating profits are more than double.
The Economist Group — which includes information providers the Economist Intelligence Unit and CQ Roll Call — had operating profits of £60m last year, compared with the FT Group’s £24m.
Other potential buyers include the three families that have long controlled most of the 50 per cent of the Economist that Pearson did not own: the Schroders, the Cadburys and the Rothschilds, one person close to the situation said. Lynn Forester de Rothschild and her husband Sir Evelyn de Rothschild control about 22 per cent of the Economist Group.
A deal is not imminent, but is expected to be agreed over the summer, the person added.
For Exor, the move comes during a period in which it is transforming its portfolio from a previously heavily industrial business to one that also includes financial services and a larger presence in media.
Fiat Chrysler Automobiles, the carmaker controlled by the Agnellis, is the biggest shareholder in RCS Mediagroup, publisher of Italian newspaper Corriere della Sera. FCA has its headquarters in the same building as the Economist magazine. Exor is also in talks to acquire reinsurance group PartnerRe for $6.8bn after a long-fought battle to scupper that company’s existing merger with another reinsurer.
Any deal would have to be approved by the four trustees of the Economist Group, including former Conservative minister Lady Bottomley and former Cabinet secretary Lord O’Donnell. The trustees’ role is to preserve “the continued independence of the ownership of the company and the editorial independence of the Economist”.
In a statement, Pearson said it was “in discussions with the Economist Group board and trustees regarding the potential sale of our 50 per cent share in the group. There is no certainty that this process will lead to a transaction.” Media groups Bloomberg, Thomson Reuters and Axel Springer were also approached about the stake, two people close to the situation said. But those companies declined to pursue an acquisition, because owning it would not give them control of the group, the person said.
Pearson acquired half of the Economist in 1957, as part of its acquisition of the Financial Times. But its stake, constituted of B shares, entitle it to name only six of the 13 members of the group’s board. The majority of the board are named by the holders of the A shares, as well as some current and former employees.
The Economist’s editorial independence is safeguarded by the fact that the trustees must approve any transfer of A or B shares, and the appointment of each new editor.

In recent years the Economist Group has been seeking to diversify away from sales of print advertising, which fell 18 per cent in 2014, by launching a foreign-language edition and a new video venture.
In January the Economist appointed Zanny Minton Beddoes as its first female editor in its 172-year history, succeeding John Micklethwait who joined Bloomberg as editor-in-chief.
Unlike the Financial Times, the magazine’s editorial independence is formally enshrined in its corporate set-up.
So strong is the magazine’s editorial department that, while most of the group has moved to Canary Wharf, it has remained in its offices in Mayfair. Managers have now all but given up on the journalists joining them in the Docklands, with one alternative to relocate the whole company somewhere else, a senior employee at the Economist Group said.

Selling the FT Group and the Economist Group stake would leave Pearson with nearly £1bn in net proceeds — strengthening its balance sheet at a time when its credit rating has a negative outlook from Moody’s, due to uncertainty in the education sector.
Pearson’s chief executive John Fallon has pledged to prioritise investments in the company’s existing education business ahead of pursuing further acquisitions.
He has also underlined Pearson’s reluctance to return cash to shareholders through buybacks or special dividends, although the company does have a policy of increasing dividends faster than the rate of inflation.

>>> S&P Index inclusions & Deletions

SIG US : To move to S&P500, PRXL and CTCT added to S&P400, ENTA and BNED added to S&P600 

- S&P MidCap 400 constituent Signet Jewelers Limited (NYSE:SIG) will replace DIRECTV (NASD:DTV) in the S&P 500; S&P SmallCap 600 constituent PAREXEL International Corp. (NASD:PRXL) will replace Signet Jewelers in the S&P MidCap 400; and Enanta Pharmaceuticals (NASD:ENTA) will replace PAREXEL International in the S&P SmallCap 600, effective after the close of trading on Tuesday, July 28. S&P 100 & 500 constituent AT&T Inc. (NYSE:T) acquired DIRECTV in a deal completed today.

- Barnes & Noble Education Inc. (NYSE:BNED) will replace A. M. Castle & Co, Inc. (NYSE:CAS) in the S&P SmallCap 600 effective after the close of trading on Friday, July 31. S&P SmallCap 600 constituent Barnes & Noble Inc. (NYSE: BKS) is spinning off Barnes & Noble Education to shareholders in a transaction expected to be completed on that date. Barnes & Noble will remain in the S&P SmallCap 600 following completion of the transaction. A.M. Castle is ranked near the bottom the S&P SmallCap 600

- Catalent Inc. (NYSE:CTLT) will replace JDS Uniphase Corp. (NASD:JDSU) in the S&P MidCap 400 and JDS Uniphase will replace Susquehanna Bancshares Inc. (NASD:SUSQ) in the S&P SmallCap 600 effective after the close of trading on Friday, July 31. S&P 500 constituent BB&T Corp. (NYSE:BBT) is acquiring Susquehanna Bancshares in a transaction expected to be completed on or about that date pending final approvals. JDS Uniphase is spinning off assets that will result in the company being more representative of the small-cap market space.- 

Lumentum Holdings Inc. (NASD:LITEV) will replace Comstock Resources Inc. (NYSE:CRK) in the S&P SmallCap 600 effective after the close of trading on Monday, August 3. New S&P SmallCap 600 constituent JDS Uniphase Corp. (NASD: JDSU) is spinning off Lumentum Holdings to shareholders in a transaction expected to be completed on that date. Post spin-off, JDS Uniphase, which is changing its name to Viavi Solutions Inc., will remain in the S&P SmallCap 600. Comstock Resources is ranked at the bottom the S&P SmallCap 600.

(Barron's) Despite Stumble, BTG’s Upside Looks Healthy

Despite Stumble, BTG’s Upside Looks Healthy
U.K. drug maker should regain momentum from an innovative new therapy for varicose veins. Short-term stock woes provide investors an entry point.

BTG ’s stock caught a cold earlier this year when the drug maker reported disappointing progress for a new product. It hasn’t quite shaken off the effects, but it can make a full recovery.

In fact, the prevailing weakness in BTG’s shares (ticker: BTG.UK) represents an attractive entry point for investors. At Friday’s close of 6.56 British pounds ($10.20), BTG’s shares trade at 23.6 times forecast 2016 earnings. That may look steep, but BTG recently has traded at multiples above 40.

BTG, which has a market value of £2.5 billion, is “too cheap,” reckons JPMorgan Cazenove analyst James D. Gordon, whose embedded-value-derived price target of £11 suggests an upside of 65%. Gordon’s estimate sounds lofty, and it is at the top end of analysts’ calculations.

But with BTG’s stellar growth outlook, it is achievable. BTG, which focuses on interventional medicines and specialty pharmaceuticals, is expected to boost earnings per share by a compound annual growth rate above 35% for the next six years.

Those expectations put Gordon’s projection into context. A consensus price target of £8.31, pointing to an upside of 25% over the next 12 months, seems relatively modest. That could be within easy reach, but it would return the stock only to the level where it started 2015.

BTG’s shares took a beating in May when the London-based company disclosed that U.S. sales of a new treatment for varicose veins fell short of expectations. Launched in the U.S. in August, Varithena—a foam injected into malfunctioning veins to divert blood flow to healthier veins nearby—generated sales through the end of March of only £1 million, a fraction of the £5 million expected.

Part of the problem has been smoothing out the reimbursement process with health insurers. It can take up to two years to obtain permanent reimbursement codes for new products. Lobbying insurers to accelerate timelines for approvals and improving physician support for reimbursement applications is key, note analysts at Deutsche Bank. BTG is doing exactly that.

An improvement in sales should be evident in the second half of 2015, and the early problems shouldn’t mask Varithena’s amazing potential. As a treatment that requires no incisions or general anesthesia, it could become a preferred option for patients.

BTG is targeting Varithena sales of over £322 million by 2021. Its success will be key to BTG achieving its target of more than £800 million in sales from its interventional-medicines business in six years’ time. In the year ended on March 31, sales from such medicines were £112.7 million.

Varithena isn’t the only exciting product in its interventional portfolio. Treatments for liver cancer, pulmonary embolisms, and emphysema are also contributing to the fast-paced growth. The company has two other divisions: specialty pharmaceuticals, whose products include snakebite treatment CroFab, and the licensing unit, which collects royalties on intellectual property. Both are growing sales at double-digit rates.

BTG’s earnings per share are expected to increase fourfold in the next four years, while sales are projected to double. According to analysts’ estimates, the company will earn 59 pence per share in fiscal 2018 on sales of £729 million. BTG earned 15 pence a share on £367.8 million in its most recent fiscal year. In the current year, it is forecast to earn 20 pence a share on sales of £445.3 million.

There is plenty of scope to grow. While seeking new breakthrough technologies, BTG is looking to expand the approved uses of existing products and is building its commercial offerings in Asia.

To fund past acquisitions, it has used its stock as currency or placed shares, so BTG doesn’t have any debt. It has been plowing all of its free cash back into growing the interventional-medicines business, so it isn’t paying dividends, although that could change in a few years. BTG is one medicine that investors won’t mind swallowing.

(Barron's) GREECE PASSED MORE

GREECE PASSED MORE economic tests on Thursday, meeting creditors’ conditions to begin negotiations on a third bailout package.

Those talks, which could unlock up to 86 billion euros ($94.28 billion) of aid for the beleaguered country, could continue for some weeks.

Not surprisingly, recent events surrounding Greece checked the economic recovery in the euro zone in July. The euro-zone purchasing managers’ index showed that economic activity slowed slightly, although output remained close to four-year highs. The hiccup illustrates that Europeans are worried about Greece, but not unduly concerned that a Greek exit from the euro zone couldn’t be managed.

Stumbles for the Chinese economy and the timing of the Federal Reserve’s expected interest-rate rise are giving investors plenty more to worry about. The Stoxx Europe 600 index ended the week down 2.7%.